Affinity Asset Advisors
Latest statistics and disclosures from Affinity Asset Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ROIV, APGE, SYRE, XENE, ERAS, and represent 25.75% of Affinity Asset Advisors's stock portfolio.
- Added to shares of these 10 stocks: TRAX (+$41M), ROIV (+$34M), ARKG (+$32M), AVTX (+$29M), LLY (+$24M), INSM (+$18M), BLTE (+$15M), IDYA (+$15M), Odyssey Therapeutics (+$14M), OMER (+$13M).
- Started 23 new stock positions in BHVN, Hemab Therapeutics Holdings, Amanat Acquisition Corp, FTH, LLY, OMER, EIKN, EVMN, ENGN, ARKG. SPRB, BOLD, SMMT, NMRA, Jatt Ii Acquisition Corp, IDYA, TRAX, ASMB, AMLX, Odyssey Therapeutics, Research Alliance Corp Iii, ASND, Celcuity.
- Reduced shares in these 10 stocks: , Centessa Pharmaceuticals (-$56M), ACLX (-$42M), APGE (-$40M), TEVA (-$35M), TERN (-$30M), Ascendis Pharma A S (-$22M), BMY (-$18M), CYTK (-$13M), COGT (-$12M).
- Sold out of its positions in ACLX, Ascendis Pharma A S, BBIO, BMY, CELC, Celcuity, Centessa Pharmaceuticals, CGON, CORT, Engene Holdings. IBRX, Kezar Life Sciences, NVO, SPY, TERN, WVE.
- Affinity Asset Advisors was a net seller of stock by $-101M.
- Affinity Asset Advisors has $2.2B in assets under management (AUM), dropping by 14.26%.
- Central Index Key (CIK): 0001773195
Tip: Access up to 7 years of quarterly data
Positions held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Affinity Asset Advisors
Affinity Asset Advisors holds 110 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Roivant Sciences SHS (ROIV) | 6.0 | $133M | +33% | 3.8M | 35.39 |
|
| Apogee Therapeutics (APGE) | 5.9 | $131M | -23% | 987k | 132.73 |
|
| Spyre Therapeutics Com New (SYRE) | 5.1 | $114M | 1.3M | 88.78 |
|
|
| Xenon Pharmaceuticals (XENE) | 4.4 | $96M | -4% | 1.6M | 60.36 |
|
| Erasca (ERAS) | 4.3 | $96M | 5.3M | 18.32 |
|
|
| Alkermes SHS (ALKS) | 3.3 | $72M | 1.4M | 52.40 |
|
|
| Insmed Com Par $.01 (INSM) | 3.1 | $69M | +35% | 650k | 106.62 |
|
| Moderna Put Option (MRNA) | 3.1 | $68M | +21% | 975k | 70.03 |
|
| Praxis Precision Medicines I Com New (PRAX) | 2.8 | $62M | +8% | 185k | 334.79 |
|
| Oruka Therapeutics (ORKA) | 2.5 | $56M | +18% | 590k | 95.17 |
|
| Anaptysbio Inc Common (ANAB) | 2.5 | $56M | -12% | 826k | 67.50 |
|
| Avalo Therapeutics Com New (AVTX) | 2.4 | $54M | +116% | 2.9M | 18.48 |
|
| Cytokinetics Com New (CYTK) | 2.1 | $47M | -21% | 550k | 85.19 |
|
| Revolution Medicines (RVMD) | 2.1 | $47M | +25% | 250k | 187.28 |
|
| Abivax Sa Sponsored Ads (ABVX) | 2.0 | $44M | -18% | 330k | 133.26 |
|
| First Tracks Biotherapeutics Ord Shs (TRAX) | 1.8 | $41M | NEW | 2.0M | 20.12 |
|
| Dianthus Therapeutics (DNTH) | 1.8 | $39M | 400k | 97.48 |
|
|
| Sutro Biopharma Com Shs (STRO) | 1.8 | $39M | +9% | 1.2M | 33.20 |
|
| Nuvalent Inc-a (NUVL) | 1.5 | $34M | -8% | 275k | 123.50 |
|
| Trevi Therapeutics (TRVI) | 1.5 | $34M | -9% | 1.8M | 18.65 |
|
| Ark Etf Tr Genomic Rev Etf Call Option (ARKG) | 1.4 | $32M | NEW | 750k | 42.06 |
|
| Ovid Therapeutics (OVID) | 1.2 | $27M | -4% | 10M | 2.69 |
|
| Lexeo Therapeutics (LXEO) | 1.2 | $27M | +14% | 5.8M | 4.66 |
|
| Celldex Therapeutics Com New (CLDX) | 1.2 | $26M | +40% | 700k | 37.21 |
|
| Belite Bio Sponsored Ads (BLTE) | 1.1 | $25M | +153% | 165k | 153.99 |
|
| Enliven Therapeutics (ELVN) | 1.1 | $25M | -14% | 500k | 50.75 |
|
| Forte Biosciences Com New (FBRX) | 1.1 | $24M | +13% | 1.1M | 21.25 |
|
| Eli Lilly & Co. Call Option (LLY) | 1.1 | $24M | NEW | 20k | 1199.43 |
|
| Nurix Therapeutics (NRIX) | 1.1 | $24M | 968k | 24.26 |
|
|
| Alto Neuroscience Com Shs (ANRO) | 1.0 | $22M | +70% | 850k | 26.39 |
|
| Madrigal Pharmaceuticals (MDGL) | 1.0 | $22M | -27% | 40k | 536.95 |
|
| Protagonist Therapeutics (PTGX) | 1.0 | $21M | 172k | 122.58 |
|
|
| Mineralys Therapeutics (MLYS) | 0.9 | $20M | 750k | 26.98 |
|
|
| Relay Therapeutics (RLAY) | 0.9 | $20M | +162% | 1.1M | 18.71 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.9 | $19M | +187% | 2.5M | 7.73 |
|
| Jade Biosciences Com New (JBIO) | 0.8 | $19M | +31% | 840k | 22.22 |
|
| Cogent Biosciences (COGT) | 0.8 | $17M | -40% | 450k | 38.70 |
|
| Uniqure Nv SHS (QURE) | 0.8 | $17M | +25% | 375k | 46.06 |
|
| Travere Therapeutics (TVTX) | 0.8 | $17M | 300k | 56.81 |
|
|
| Cullinan Oncology (CGEM) | 0.7 | $16M | +12% | 876k | 18.21 |
|
| Savara (SVRA) | 0.7 | $16M | 2.5M | 6.16 |
|
|
| Ideaya Biosciences (IDYA) | 0.7 | $15M | NEW | 400k | 37.27 |
|
| Perspective Therapeutics Com New (CATX) | 0.6 | $14M | +33% | 4.2M | 3.41 |
|
| Odyssey Therapeutics Common Stock | 0.6 | $14M | NEW | 766k | 18.71 |
|
| Cogent Biosciences Note 1.625%11/1 (Principal) | 0.6 | $14M | +57% | 11M | 1.24 |
|
| Omeros Corporation Put Option (OMER) | 0.6 | $13M | NEW | 1.4M | 9.51 |
|
| Helix Acquisition Corp Iii Usd Cl A Ord Shs (HLXC) | 0.6 | $13M | 1.3M | 10.64 |
|
|
| Equillium (EQ) | 0.6 | $13M | +234% | 4.1M | 3.20 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.6 | $13M | +48% | 148k | 85.81 |
|
| Eliem Therapeutics (CLYM) | 0.6 | $13M | +38% | 972k | 13.04 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 0.6 | $13M | -73% | 374k | 33.88 |
|
| Veradermics Common Stock (MANE) | 0.6 | $12M | +42% | 100k | 122.94 |
|
| Arrowhead Pharmaceuticals (ARWR) | 0.6 | $12M | -25% | 150k | 81.51 |
|
| Omeros Corp Note 9.500% 6/1 (Principal) | 0.6 | $12M | 6.5M | 1.87 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.5 | $12M | +75% | 1.8M | 6.81 |
|
| Damora Therapeutics Com New (DMRA) | 0.5 | $11M | -5% | 425k | 26.01 |
|
| Eupraxia Pharmaceuticals (EPRX) | 0.5 | $11M | +3% | 1.7M | 6.61 |
|
| Vera Therapeutics Cl A (VERA) | 0.5 | $11M | 250k | 42.91 |
|
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.5 | $10M | +125% | 5.5M | 1.86 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.4 | $9.3M | 275k | 33.89 |
|
|
| Korro Bio (KRRO) | 0.4 | $9.3M | 707k | 13.18 |
|
|
| Anteris Technologies Global (AVR) | 0.4 | $9.0M | 912k | 9.85 |
|
|
| Zura Bio Class A Ord Shs (ZURA) | 0.4 | $8.6M | -42% | 1.5M | 5.90 |
|
| Ascendis Pharma A/s Ord Shs (ASND) | 0.4 | $8.0M | NEW | 30k | 266.72 |
|
| Ibio Com New (IBIO) | 0.3 | $7.0M | +28% | 4.0M | 1.75 |
|
| Generate Biomedicines Com Shs (GENB) | 0.3 | $6.7M | +14% | 400k | 16.87 |
|
| Evommune Com Shs Put Option (EVMN) | 0.3 | $6.6M | NEW | 500k | 13.29 |
|
| Tyra Biosciences (TYRA) | 0.3 | $6.4M | -22% | 200k | 31.94 |
|
| Sol-gel Technologies Shs New (SLGL) | 0.3 | $6.3M | +142% | 85k | 74.14 |
|
| Sab Biotherapeutics Com New (SABS) | 0.3 | $5.9M | +165% | 1.5M | 3.90 |
|
| Macrogenics (MGNX) | 0.3 | $5.6M | +143% | 1.2M | 4.62 |
|
| Crispr Therapeutics Namen Akt (CRSP) | 0.2 | $5.5M | -33% | 100k | 54.54 |
|
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.2 | $5.3M | 245k | 21.81 |
|
|
| Assembly Biosciences Com New (ASMB) | 0.2 | $5.2M | NEW | 190k | 27.48 |
|
| Rezolute Com New (RZLT) | 0.2 | $5.2M | -35% | 1.0M | 5.20 |
|
| Precision Biosciences Com New (DTIL) | 0.2 | $5.1M | +8% | 647k | 7.86 |
|
| Hemab Therapeutics Hldgs Com Shs | 0.2 | $5.1M | NEW | 138k | 36.73 |
|
| Miragen Therapeutics (VRDN) | 0.2 | $4.6M | 250k | 18.37 |
|
|
| Arrivent Biopharma (AVBP) | 0.2 | $4.3M | -28% | 125k | 34.74 |
|
| Verrica Pharmaceuticals Com Shs (VRCA) | 0.2 | $4.3M | 707k | 6.12 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 0.2 | $4.3M | -72% | 301k | 14.15 |
|
| Mbx Biosciences (MBX) | 0.2 | $4.1M | -50% | 75k | 55.20 |
|
| Research Alliance Corp Iii Ord Shs Cl A | 0.2 | $4.0M | NEW | 370k | 10.70 |
|
| Immunovant (IMVT) | 0.2 | $3.9M | 100k | 38.53 |
|
|
| Amanat Acquisition Corp Cl A Ord | 0.2 | $3.8M | NEW | 375k | 10.16 |
|
| Biohaven (BHVN) | 0.2 | $3.7M | NEW | 250k | 14.88 |
|
| Faeth Therapeutics Com New (FTH) | 0.2 | $3.6M | NEW | 144k | 25.00 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.1 | $3.1M | -37% | 313k | 9.77 |
|
| Alector (ALEC) | 0.1 | $3.0M | +202% | 1.5M | 2.01 |
|
| Spyglass Pharma Com Shs (SGP) | 0.1 | $2.9M | -47% | 132k | 22.26 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.1 | $2.8M | 75k | 37.42 |
|
|
| Oaktree Acquisition Corp Iii Unit 10/04/2029 (OACCU) | 0.1 | $2.8M | 250k | 11.00 |
|
|
| Celcuity Note 0.250% 8/0 (Principal) | 0.1 | $2.3M | NEW | 2.0M | 1.14 |
|
| Jatt Ii Acquisition Corp Ord Shs | 0.1 | $2.3M | NEW | 200k | 11.36 |
|
| Neumora Therapeutics (NMRA) | 0.1 | $1.8M | NEW | 1.1M | 1.70 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.1 | $1.8M | NEW | 99k | 17.96 |
|
| Adlai Nortye Sponsored Ads (ANL) | 0.1 | $1.8M | -6% | 154k | 11.50 |
|
| Spruce Biosciences Com New (SPRB) | 0.1 | $1.6M | NEW | 30k | 54.00 |
|
| Summit Therapeutics Call Option (SMMT) | 0.1 | $1.5M | NEW | 100k | 14.57 |
|
| Eikon Therapeutics (EIKN) | 0.1 | $1.3M | NEW | 98k | 13.05 |
|
| Onkure Therapeutics Com Cl A (OKUR) | 0.0 | $1.1M | 241k | 4.56 |
|
|
| Engene Therapeutics (ENGN) | 0.0 | $1.0M | NEW | 600k | 1.73 |
|
| X4 Pharmaceuticals Com New (XFOR) | 0.0 | $677k | 145k | 4.67 |
|
|
| Boundless Bio (BOLD) | 0.0 | $625k | NEW | 250k | 2.50 |
|
| Lenz Therapeutics (LENZ) | 0.0 | $568k | 100k | 5.68 |
|
|
| Q32 Bio (QTTB) | 0.0 | $354k | 28k | 12.74 |
|
|
| Health Sciences Acq Corp 2 (OBIO) | 0.0 | $144k | -91% | 33k | 4.32 |
|
| Nextcure Com New (NXTC) | 0.0 | $67k | -82% | 42k | 1.60 |
|
| Adagio Med Hldgs (ADGM) | 0.0 | $52k | 80k | 0.65 |
|
|
| Rocket Pharmaceuticals *w Exp 09/02/202 (RCKTW) | 0.0 | $277.500000 | 75k | 0.00 |
|
Past Filings by Affinity Asset Advisors
SEC 13F filings are viewable for Affinity Asset Advisors going back to 2020
- Affinity Asset Advisors 2026 Q2 filed Aug. 13, 2026
- Affinity Asset Advisors 2026 Q1 filed May 14, 2026
- Affinity Asset Advisors 2025 Q4 filed Feb. 13, 2026
- Affinity Asset Advisors 2025 Q3 filed Nov. 13, 2025
- Affinity Asset Advisors 2025 Q2 filed Aug. 13, 2025
- Affinity Asset Advisors 2025 Q1 filed May 14, 2025
- Affinity Asset Advisors 2024 Q4 filed Feb. 13, 2025
- Affinity Asset Advisors 2024 Q3 filed Nov. 13, 2024
- Affinity Asset Advisors 2024 Q2 filed Aug. 14, 2024
- Affinity Asset Advisors 2024 Q1 filed May 14, 2024
- Affinity Asset Advisors 2023 Q4 filed Feb. 13, 2024
- Affinity Asset Advisors 2023 Q3 filed Nov. 14, 2023
- Affinity Asset Advisors 2023 Q2 restated filed Aug. 21, 2023
- Affinity Asset Advisors 2023 Q2 filed Aug. 14, 2023
- Affinity Asset Advisors 2023 Q1 filed May 15, 2023
- Affinity Asset Advisors 2022 Q4 filed Feb. 13, 2023